You have full text access to this OnlineOpen article

Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily

  1. William C. Stewart1,2,*,
  2. Jeanette A. Stewart1,3,4,
  3. Douglas Day3,4,
  4. Elizabeth D. Sharpe5

Article first published online: 29 MAY 2003

DOI: 10.1034/j.1600-0420.2003.00065.x

Issue

Acta Ophthalmologica Scandinavica

Acta Ophthalmologica Scandinavica

Volume 81, Issue 3, pages 242–246, June 2003

Additional Information

How to Cite

Stewart, W. C., Stewart, J. A., Day, D. and Sharpe, E. D. (2003), Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmologica Scandinavica, 81: 242–246. doi: 10.1034/j.1600-0420.2003.00065.x

Author Information

  1. 1

    Pharmaceutical Research Network, LLC, Charleston, South Carolina, USA

  2. 2

    Department of Ophthalmology, University of South Carolina, Columbia, South Carolina, USA

  3. 3

    Omni Eye Services, Atlanta, Georgia, USA

  4. 4

    Atlanta Research Company, Atlanta, Georgia, USA

  5. 5

    Ophthalmology Consultants, Charleston, South Carolina, USA

*William C. Stewart MD Pharmaceutical Research Network LLC 1639 Tatum Street Charleston South Carolina 29412–2464 USA Tel: + 1 843 762 6500 Fax: + 1 843 762 7444 Email: prnc@bellsouth.net

Publication History

  1. Issue published online: 29 MAY 2003
  2. Article first published online: 29 MAY 2003
  3. Received on October 10th, 2002. Accepted on February 4th, 2003.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (116K)

Keywords:

  • timolol;
  • latanoprost;
  • brimonidine

Abstract.

Purpose:  To evaluate the efficacy and safety of the timolol maleate/latanoprost fixed combination (TLFC) given once each evening versus brimonidine and timolol solution given twice daily as concomitant therapy in primary open-angle glaucoma or ocular hypertension patients.

Methods:  Qualified subjects were begun on timolol alone twice daily for 1 month and then randomized to either TLFC or brimonidine and timolol concomitant therapy for 6 weeks. Patients were then switched to the other treatment regimen. Intraocular pressures (IOPs) were measured every 2 hours between 08 : 00 and 20 : 00 hours at baseline and at the end of periods 1 and 2.

Results:  This study found that in 32 subjects the IOP diurnal curve on timolol alone (20.9 ± 2.8 mmHg) decreased to 17.9 ± 3.2 mmHg when patients were treated with TLFC and to 19.0 ± 2.4 mmHg when patients were treated with brimonidine and timolol (p = 0.02). Intraocular pressures at individual time-points were statistically similar between the groups at the 08 : 00 trough and 2 and 4 hours after dosing. However, beyond 4 hours after dosing, TLFC-treated subjects demonstrated a trend towards lower IOPs at each 2-hour time-point that was not statistically significant after a Bonferroni correction (p ≤ 0.05). The incidence of both solicited and unsolicited side-effects was similar between groups.

Conclusion:  This study suggests that TLFC given in the evening reduces the mean daytime diurnal IOP more than brimonidine and timolol given concomitantly twice daily.

View Full Article (HTML) Get PDF (116K)